Vitro Diagnostics, Inc. (OTCBB:VODG), dba Vitro Biopharma, announced the opening of a new corporate facility in the Coors Technology Center located in Golden Colorado. The new facility will be used for manufacturing, research & development and administrative functions. It is especially suited to support FDA-compliant manufacturing of the Company’s human stem cell products for various commercial applications in medical research, pharmaceutical manufacturing, drug discovery and cell therapy of diabetes and other diseases. The Company is leasing the facility from a third party at a rate comparable to its prior facility leases.
Dr. Jim Musick, Vitro’s President and CEO, said, “We are very pleased to announce the opening of our new facility which affords us the appropriate infrastructure to provide stem cell products that are manufactured to stringent specifications when combined with new manufacturing equipment that the Company has recently acquired. The new facility also provides for future manufacturing of products for therapeutic applications. This is an essential development in our transition from research and development to commercial manufacturing of biological products, given our recent R&D advances. The new facility is a decisive component of our future growth.”
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB:VODG) http://www.vitrodiag.com, has generated over 30 adult pancreatic stem cell lines that are distinct from the limited number of embryonic stem cell lines that are presently approved for federally funded research. These cell lines may have commercial application in drug development and discovery, diabetes research and therapy. The Company developed and manufactures the VITROCELL™ brand of human cell lines consisting of pancreatic-derived cell lines and related products that are sold for various research and commercial applications.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward- looking statements are identified by words such as “intends,”“anticipates,” “believes,”“expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Dr. James Musick, Chief Executive Officer,
303-999-2130
jim@vitrodiag.com
